Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma
Authors
Keywords
-
Journal
HEPATOLOGY
Volume 64, Issue 3, Pages 774-784
Publisher
Wiley
Online
2016-04-15
DOI
10.1002/hep.28600
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib
- (2016) Sadahisa Ogasawara et al. INVESTIGATIONAL NEW DRUGS
- A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258)
- (2015) Jeffrey R. Infante et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Refining sorafenib therapy: lessons from clinical practice
- (2015) Luigi Bolondi et al. Future Oncology
- Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
- (2015) Calin Cainap et al. JOURNAL OF CLINICAL ONCOLOGY
- Surgical Treatment for Hepatocellular Carcinoma
- (2015) MazenM Hassanain et al. Saudi Journal of Gastroenterology
- Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma
- (2014) Matthew I. Milowsky et al. EUROPEAN JOURNAL OF CANCER
- Sa1701 Cytotoxic T Lymphocyte Antigen-4 (Ctla-4) Signaling Effectively Retains Regulatory T Cells (Treg) to Alleviate Liver Injury of Patients With Acute-on-Chronic Hepatitis B (Achb)
- (2014) Jing Li et al. GASTROENTEROLOGY
- Development of systemic therapy for hepatocellular carcinoma at 2013: Updates and insights
- (2014) Stephen L Chan WORLD JOURNAL OF GASTROENTEROLOGY
- Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib
- (2013) Y-K Kang et al. BRITISH JOURNAL OF CANCER
- Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma
- (2013) E. Angevin et al. CLINICAL CANCER RESEARCH
- Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer
- (2013) F. Andre et al. CLINICAL CANCER RESEARCH
- Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
- (2013) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
- (2013) Ann-Lii Cheng et al. JOURNAL OF CLINICAL ONCOLOGY
- Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
- (2012) J. M. Llovet et al. CLINICAL CANCER RESEARCH
- A Novel Monoclonal Antibody to Fibroblast Growth Factor 2 Effectively Inhibits Growth of Hepatocellular Carcinoma Xenografts
- (2012) L. Wang et al. MOLECULAR CANCER THERAPEUTICS
- Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma
- (2011) K. B. Kim et al. CLINICAL CANCER RESEARCH
- Management of hepatocellular carcinoma: An update
- (2011) Jordi Bruix et al. HEPATOLOGY
- Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma
- (2011) Hung Huynh et al. JOURNAL OF HEPATOLOGY
- Dovitinib Induces Apoptosis and Overcomes Sorafenib Resistance in Hepatocellular Carcinoma through SHP-1-Mediated Inhibition of STAT3
- (2011) W.-T. Tai et al. MOLECULAR CANCER THERAPEUTICS
- Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis
- (2010) Christine Gauglhofer et al. HEPATOLOGY
- A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
- (2008) D. Sarker et al. CLINICAL CANCER RESEARCH
- Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. JNCI-Journal of the National Cancer Institute
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started